Interpretation of an evidence-based guideline for the diagnosis and treatment of demyelinating optic neuritis in China (2021)_Chinese Journal of Ocular Fundus Diseases

Authors：

Song Honglu , Wei Shihui , Sun Mingming , Xu Quangang ,  Zhou Huanfen

Department of Ophthalmology, Third Medical Center of Chinese PLA General Hospital, Beijing 100853, China;

Corresponding?author：

Zhou Huanfen, Email: zhouzhoueye@163.com

Keywords：

Optic neuritis; Neuromyelitis optica; Practice guidelines as topic; Evidence-based medicine

DOI：

10.3760/cma.j.cn511434-20210830-00475

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The first edition of “The Chinese expert consensus on the diagnosis and treatment of optic neuritis” have been published in Chinese Journal of Ophthalmology in 2014. Seven years later, more evidence-based medicine has been accumulated in the treatment of optic neuritis. It is necessary to update or formulate guidelines to guide clinical practice. Based on the methods and procedures for developing evidence -based guidelines, Neuro-Ophthalmology Group of Ophthalmology Branch of Chinese Medical Association and Evidence-based Medicine Centre of Lanzhou University/World Health Organization Collaborating Centre for Guideline Implementation and Knowledge Translation created the first “An evidence-based guideline for the diagnosis and treatment of demyelinating optic neuritis in China (2021)”, which aimed to improve the level of clinical diagnosis and treatments of demyelinating optic neuritis. This guideline proposes a new subtype classification of demyelinating optic neuritis to guide precision treatment. It also gives new suggestions about clinical treatment hotspots in the acute and chronic phases, including the application of immunosuppressants and rituximab and other biological agents.

Citation： Song Honglu, Wei Shihui, Sun Mingming, Xu Quangang, Zhou Huanfen. Interpretation of an evidence-based guideline for the diagnosis and treatment of demyelinating optic neuritis in China (2021). Chinese Journal of Ocular Fundus Diseases, 2021, 37(10): 753-757. doi: 10.3760/cma.j.cn511434-20210830-00475 Copy

1.	宋宏魯, 魏世輝. 我國神經眼科發展的現狀與挑戰[J]. 中國研究型醫院, 2021, 8(4): 69-72. DOI: 10.19450/j.cnki.jcrh.2021.04.017.Song HL, Wei SH. Current status and challenges of neuro-ophthalmology development in China[J]. Journal of Chinese Research Hospitals, 2021, 8(4): 69-72. DOI: 10.19450/j.cnki.jcrh.2021.04.017.
2.	中華醫學會眼科學分會神經眼科學組. 視神經炎診斷和治療專家共識 (2014年)[J]. 中華眼科雜志, 2014, 50(6): 459-463. DOI: 10.3760/cma.j.issn.0412-4081.2014.06.013.Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association. Expert consensus on diagnosis and treatment of optic neuritis (2014)[J]. Chin J Ophthalmol, 2014, 50(6): 459-463. DOI: 10.3760/cma.j.issn.0412-4081.2014.06.013.
3.	Toosy AT, Mason DF, Miller DH. Optic neuritis[J]. Lancet Neurol, 2014, 13(1): 83-99. DOI: 10.1016/S1474-4422(13)70259-X.
4.	Petzold A, Plant GT. Diagnosis and classification of autoimmune optic neuropathy[J]. Autoimmun Rev, 2014, 13: 539-545. DOI: 10.1016/j.autrev.2014.01.009.
5.	Hassan MB, Stern C, Flanagan EP, et al. Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies[J]. Am J Ophthalmol, 2020, 220: 110-114. DOI: 10.1016/j.ajo.2020.07.014.
6.	中華醫學會眼科學分會神經眼科學組, 蘭州大學循證醫學中心/世界衛生組織指南實施與知識轉化合作中心. 中國脫髓鞘性視神經炎診斷和治療循證指南 (2021年)[J]. 中華眼科雜志, 2021, 57(3): 171-186. DOI: 10.3760/cma.j.cn112142-20201124-00769.Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association, Evidence-based Medicine Center of Lanzhou University/World Health Organization Collaborating Centre for Guideline Implementation and Knowledge Translation. Evidence-based guidelines for diagnosis and treatment of demyelinating optic neuritis in China (2021)[J]. Chin J Ophthalmol, 2021, 57(3): 171-186. DOI: 10.3760/cma.j.cn112142-20201124-00769.
7.	Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group[J]. N Engl J Med, 1992, 326: 581-588. DOI: 10.1056/NEJM199202273260901.
8.	Wakakura M, Ishikawa S, Oono S, et al. Incidence of acute idiopathic optic neuritis and its therapy in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG)[J]. Nippon Ganka Gakkai Zasshi, 1995, 99: 93-97.
9.	Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. DOI: 10.1212/WNL.0000000000001729.
10.	中國免疫學會神經免疫學分會, 中華醫學會神經病學分會神經免疫學組, 中國醫師協會神經內科分會神經免疫專業委員會. 中國視神經脊髓炎譜系疾病診斷與治療指南[J]. 中國神經免疫學和神經病學雜志, 2016, 23(3): 155-166. DOI: 10.3969/j.issn.1006-2963.2016.03.001.The Neuroimmunology Branch of the Chinese Society of Immunology, The Neuroimmunology Group of the Neurology Branch of the Chinese Medical Association, The Neuroimmunology Professional Committee of the Neurology Branch of the Chinese Medical Doctor Association. Guidelines for the diagnosis and treatment of neuromyelitis optica spectrum diseases in China[J]. Chin J Neuroimmunol & Neurol, 2016, 23(3): 155-166. DOI: 10.3969/j.issn.1006-2963.2016.03.001.
11.	Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing[J/OL]. J Neuroinflammation, 2018, 15(1): 134[2018-05-03]. https://pubmed.ncbi.nlm.nih.gov/29724224/. DOI: 10.1186/s12974-018-1144-2.
12.	López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders[J]. JAMA Neurol, 2018, 75: 1355-1363. DOI: 10.1001/jamaneurol.2018.1814.
13.	中國免疫學會神經免疫分會. 抗髓鞘少突膠質細胞糖蛋白免疫球蛋白G抗體相關疾病診斷和治療中國專家共識[J]. 中國神經免疫學和神經病學雜志, 2020, 27(2): 86-95. DOI: 10.3969/j.issn.1006-2963.2020.02.002.The Neuroimmunology Branch of the Chinese Society of Immunology. Chinese expert consensus on diagnosis and treatment of diseases related to anti-myelin oligodendrocyte glycoprotein immunoglobulin G antibody[J]. Chin J Neuroimmunol & Neurol, 2020, 27(2): 86-95. DOI: 10.3969/j.issn.1006-2963.2020.02.002.
14.	Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria[J]. Lancet Neurol, 2018, 17: 162-173. DOI: 10.1016/S1474-4422(17)30470-2.
15.	Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported[J]. J Neurol, 2014, 261: 17-26. DOI: 10.1007/s00415-013-6957-4.
16.	Zhou H, Zhao S, Yin D, et al. Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages[J]. J Neurol, 2016, 263: 1382-1389. DOI: 10.1007/s00415-016-8155-7.
17.	Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders[J]. J Neurol Neurosurg Psychiatry, 2018, 89: 346-351. DOI: 10.1136/jnnp-2017-316286.
18.	Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous IVMP and PLEX[J/OL]. Mult Scler Relat Disord, 2020, 38: 101506[2019-11-06]. https://pubmed.ncbi.nlm.nih.gov/31731214/. DOI: 10.1016/j.msard.2019.101506.
19.	Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis[J]. Neurology, 2001, 56: 1514-1522. DOI: 10.1212/wnl.56.11.1514.
20.	Ciron J, Audoin B, Bourre B, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders[J]. Rev Neurol (Paris), 2018, 174(4): 255-264. DOI: 10.1016/j.neurol.2017.11.005.
21.	Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2020, 19: 298-306. DOI: 10.1016/S1474-4422(20)30066-1.
22.	Liu H, Zhou H, Wang J, et al. Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy[J]. Br J Ophthalmol, 2019, 103: 1423-1428. DOI: 10.1136/bjophthalmol-2018-313142.
23.	Lee HJ, Kim B, Waters P, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies[J/OL]. J Neuroinflammation, 2018, 15(1): 302[2018-10-31].https://pubmed.ncbi.nlm.nih.gov/30382857/. DOI: 10.1186/s12974-018-1335-x.
24.	Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients[J/OL]. Mult Scler Relat Disord, 2020, 44: 102251[2020-07-02].https://pubmed.ncbi.nlm.nih.gov/32629363/. DOI: 10.1016/j.msard.2020.102251.
25.	Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder[J]. N Engl J Med, 2019, 381: 614-625. DOI: 10.1056/NEJMoa1900866.
26.	Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial[J]. Lancet, 2019, 394: 1352-1363. DOI: 10.1016/S0140-6736(19)31817-3.
27.	Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial[J]. Lancet Neurol, 2020, 19(5): 402-412. DOI: 10.1016/S1474-4422(20)30078-8.
28.	Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder[J]. N Engl J Med, 2019, 381: 2114-2124. DOI: 10.1056/NEJMoa1901747.
29.	中國免疫學會神經免疫分會, 中華醫學會神經病學分會神經免疫學組. 多發性硬化診斷和治療中國專家共識(2018版)[J]. 中國神經免疫學和神經病學雜志, 2018, 25(6): 387-394. DOI: 10.3969/j.issn.1006-2963.2018.06.001.3969/j. issn. 1006-2963.2018. 06.001 The Neuroimmunology Branch of the Chinese Society of Immunology, The Neuroimmunology Group of the Neurology Branch of the Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of multiple sclerosis (2018)[J]. Chin J Neuroimmunol & Neurol, 2018, 25(6): 387-394. DOI: 10.3969/j.issn.1006-2963.2018.06.001.

1. 宋宏魯, 魏世輝. 我國神經眼科發展的現狀與挑戰[J]. 中國研究型醫院, 2021, 8(4): 69-72. DOI: 10.19450/j.cnki.jcrh.2021.04.017.Song HL, Wei SH. Current status and challenges of neuro-ophthalmology development in China[J]. Journal of Chinese Research Hospitals, 2021, 8(4): 69-72. DOI: 10.19450/j.cnki.jcrh.2021.04.017.
2. 中華醫學會眼科學分會神經眼科學組. 視神經炎診斷和治療專家共識 (2014年)[J]. 中華眼科雜志, 2014, 50(6): 459-463. DOI: 10.3760/cma.j.issn.0412-4081.2014.06.013.Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association. Expert consensus on diagnosis and treatment of optic neuritis (2014)[J]. Chin J Ophthalmol, 2014, 50(6): 459-463. DOI: 10.3760/cma.j.issn.0412-4081.2014.06.013.
3. Toosy AT, Mason DF, Miller DH. Optic neuritis[J]. Lancet Neurol, 2014, 13(1): 83-99. DOI: 10.1016/S1474-4422(13)70259-X.
4. Petzold A, Plant GT. Diagnosis and classification of autoimmune optic neuropathy[J]. Autoimmun Rev, 2014, 13: 539-545. DOI: 10.1016/j.autrev.2014.01.009.
5. Hassan MB, Stern C, Flanagan EP, et al. Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies[J]. Am J Ophthalmol, 2020, 220: 110-114. DOI: 10.1016/j.ajo.2020.07.014.
6. 中華醫學會眼科學分會神經眼科學組, 蘭州大學循證醫學中心/世界衛生組織指南實施與知識轉化合作中心. 中國脫髓鞘性視神經炎診斷和治療循證指南 (2021年)[J]. 中華眼科雜志, 2021, 57(3): 171-186. DOI: 10.3760/cma.j.cn112142-20201124-00769.Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association, Evidence-based Medicine Center of Lanzhou University/World Health Organization Collaborating Centre for Guideline Implementation and Knowledge Translation. Evidence-based guidelines for diagnosis and treatment of demyelinating optic neuritis in China (2021)[J]. Chin J Ophthalmol, 2021, 57(3): 171-186. DOI: 10.3760/cma.j.cn112142-20201124-00769.
7. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group[J]. N Engl J Med, 1992, 326: 581-588. DOI: 10.1056/NEJM199202273260901.
8. Wakakura M, Ishikawa S, Oono S, et al. Incidence of acute idiopathic optic neuritis and its therapy in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG)[J]. Nippon Ganka Gakkai Zasshi, 1995, 99: 93-97.
9. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. DOI: 10.1212/WNL.0000000000001729.
10. 中國免疫學會神經免疫學分會, 中華醫學會神經病學分會神經免疫學組, 中國醫師協會神經內科分會神經免疫專業委員會. 中國視神經脊髓炎譜系疾病診斷與治療指南[J]. 中國神經免疫學和神經病學雜志, 2016, 23(3): 155-166. DOI: 10.3969/j.issn.1006-2963.2016.03.001.The Neuroimmunology Branch of the Chinese Society of Immunology, The Neuroimmunology Group of the Neurology Branch of the Chinese Medical Association, The Neuroimmunology Professional Committee of the Neurology Branch of the Chinese Medical Doctor Association. Guidelines for the diagnosis and treatment of neuromyelitis optica spectrum diseases in China[J]. Chin J Neuroimmunol & Neurol, 2016, 23(3): 155-166. DOI: 10.3969/j.issn.1006-2963.2016.03.001.
11. Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing[J/OL]. J Neuroinflammation, 2018, 15(1): 134[2018-05-03]. https://pubmed.ncbi.nlm.nih.gov/29724224/. DOI: 10.1186/s12974-018-1144-2.
12. López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders[J]. JAMA Neurol, 2018, 75: 1355-1363. DOI: 10.1001/jamaneurol.2018.1814.
13. 中國免疫學會神經免疫分會. 抗髓鞘少突膠質細胞糖蛋白免疫球蛋白G抗體相關疾病診斷和治療中國專家共識[J]. 中國神經免疫學和神經病學雜志, 2020, 27(2): 86-95. DOI: 10.3969/j.issn.1006-2963.2020.02.002.The Neuroimmunology Branch of the Chinese Society of Immunology. Chinese expert consensus on diagnosis and treatment of diseases related to anti-myelin oligodendrocyte glycoprotein immunoglobulin G antibody[J]. Chin J Neuroimmunol & Neurol, 2020, 27(2): 86-95. DOI: 10.3969/j.issn.1006-2963.2020.02.002.
14. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria[J]. Lancet Neurol, 2018, 17: 162-173. DOI: 10.1016/S1474-4422(17)30470-2.
15. Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported[J]. J Neurol, 2014, 261: 17-26. DOI: 10.1007/s00415-013-6957-4.
16. Zhou H, Zhao S, Yin D, et al. Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages[J]. J Neurol, 2016, 263: 1382-1389. DOI: 10.1007/s00415-016-8155-7.
17. Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders[J]. J Neurol Neurosurg Psychiatry, 2018, 89: 346-351. DOI: 10.1136/jnnp-2017-316286.
18. Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous IVMP and PLEX[J/OL]. Mult Scler Relat Disord, 2020, 38: 101506[2019-11-06]. https://pubmed.ncbi.nlm.nih.gov/31731214/. DOI: 10.1016/j.msard.2019.101506.
19. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis[J]. Neurology, 2001, 56: 1514-1522. DOI: 10.1212/wnl.56.11.1514.
20. Ciron J, Audoin B, Bourre B, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders[J]. Rev Neurol (Paris), 2018, 174(4): 255-264. DOI: 10.1016/j.neurol.2017.11.005.
21. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial[J]. Lancet Neurol, 2020, 19: 298-306. DOI: 10.1016/S1474-4422(20)30066-1.
22. Liu H, Zhou H, Wang J, et al. Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy[J]. Br J Ophthalmol, 2019, 103: 1423-1428. DOI: 10.1136/bjophthalmol-2018-313142.
23. Lee HJ, Kim B, Waters P, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies[J/OL]. J Neuroinflammation, 2018, 15(1): 302[2018-10-31].https://pubmed.ncbi.nlm.nih.gov/30382857/. DOI: 10.1186/s12974-018-1335-x.
24. Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients[J/OL]. Mult Scler Relat Disord, 2020, 44: 102251[2020-07-02].https://pubmed.ncbi.nlm.nih.gov/32629363/. DOI: 10.1016/j.msard.2020.102251.
25. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder[J]. N Engl J Med, 2019, 381: 614-625. DOI: 10.1056/NEJMoa1900866.
26. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial[J]. Lancet, 2019, 394: 1352-1363. DOI: 10.1016/S0140-6736(19)31817-3.
27. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial[J]. Lancet Neurol, 2020, 19(5): 402-412. DOI: 10.1016/S1474-4422(20)30078-8.
28. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder[J]. N Engl J Med, 2019, 381: 2114-2124. DOI: 10.1056/NEJMoa1901747.
29. 中國免疫學會神經免疫分會, 中華醫學會神經病學分會神經免疫學組. 多發性硬化診斷和治療中國專家共識(2018版)[J]. 中國神經免疫學和神經病學雜志, 2018, 25(6): 387-394. DOI: 10.3969/j.issn.1006-2963.2018.06.001.3969/j. issn. 1006-2963.2018. 06.001 The Neuroimmunology Branch of the Chinese Society of Immunology, The Neuroimmunology Group of the Neurology Branch of the Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of multiple sclerosis (2018)[J]. Chin J Neuroimmunol & Neurol, 2018, 25(6): 387-394. DOI: 10.3969/j.issn.1006-2963.2018.06.001.

Previous Article
Progress and challenges in diagnosis and treatment of Leber's hereditary optic neuropathy
Next Article
The effect of oral glucocorticoids on acute non-arteritic anterior ischemic optic neuropathy

Chinese Journal of Ocular Fundus Diseases

Interpretation of an evidence-based guideline for the diagnosis and treatment of demyelinating optic neuritis in China (2021)

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content